玻璃体注射Bevacizumab治疗26例Ⅰ区早产儿视网膜病变

Clinical report of intravitreal Bevacizumab for 26 cases with retinopathy of prematurity in Zone Ⅰ

目的:评价玻璃体注射bevacizumab治疗26例Ⅰ区早产儿视网膜病变(retinopathy of prematurity,ROP)的治疗效果。方法:通过回顾性研究,对2013-09/2014-10确诊为Ⅰ区阈值期ROP并行玻璃体注射bevacizumab治疗的26例患儿分三组(阈值前期Ⅰ型ROP、阈值期ROP、急进型后极部早产儿视网膜病变-APROP),进行术后效果分析比较。结果:治疗Ⅰ区高危性阈值期ROP患儿26例52眼。其中阈值前期Ⅰ型ROP 3例6眼,阈值期ROP 15例30眼,APROP 8例16眼。治疗阈值期Ⅰ型ROP、阈值期ROP和APROP的一次手术治愈率分别为100%(6/6)、60%(18/30)和75%(12/16),三组之间手术治愈率无统计学差异(P>0.05)。结论:玻璃体腔内注射bevacizumab治疗Ⅰ区ROP的临床疗效明确,比传统光凝术治疗具有一定优越性,可作为I区ROP的一线治疗方法。

AIM： To investigate the clinical effects of intravitreal Bevacizumab for 26 cases with retinopathy of prematurity （ROP） in Zone Ⅰ. METHODS：A retrospective study. Totally 26 ROP infants between September 2013 and October 2014 diagnosed as high - risk ROP in Zone Ⅰ had been treated with intravitreal bevacizumab. They were divided into three groups, pre - threshold ROP, threshold ROP and acute posterior ROP （ APROP ）. Postoperative effects were compared. RESULTS：There were 26 infants （52 eyes） diagnosed as ROP in Zone Ⅰ, including 3 infants（ 6 eyes） with pre -threshold ROP, 15 infants （30 eyes） with threshold ROP and 8 infants （16 eyes） with APROP. The first operation recovery rate of three groups respectively were 100% （6 /6）, 60% （ 18 / 30 ） and 75% （ 12 / 16 ）, which were not significantly different （P〉0. 05）. CONCLUSION：Intravitreal bevacizumab for ROP in ZoneⅠ seems effective and has some advantages over conventional laser treatment, which could be first line treatment for high-risk ROP in Zone Ⅰ.